|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Internal Medicine III,
Laboratory of Leukemogenesis, Technical University of Munich, Germany;
and the Department of Pathology, St Jude Children's Research Hospital,
Memphis, TN.
More than half of anaplastic large-cell lymphomas (ALCLs)
have a chromosomal translocation t(2;5) that leads to the expression of
a hybrid protein composed of the nucleolar phosphoprotein nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK) that exhibits an unregulated tyrosine kinase activity. We have previously identified PLC- Anaplastic large-cell lymphoma (ALCL) constitutes a
subgroup of non-Hodgkin lymphoma that often express the membrane
antigen CD30. Over half of these lymphomas display a typical
chromosomal translocation t(2;5)(p23;q35) that fuses nucleophosmin
(NPM) sequences on chromosome 5 to anaplastic lymphoma kinase
(ALK) sequences on chromosome 2.1-6 NPM is an ubiquitously
expressed nucleolar protein responsible for protein shuttling between
the cytoplasm and the nucleus.7-10 ALK is a receptor
tyrosine kinase, the expression of which is normally restricted to
neural tissues.11,12 Fusion of NPM to ALK results in the
dimerization and constitutive activation of the NPM-ALK oncoprotein.
NPM-ALK is capable of transforming fibroblasts and inducing a
lymphoma-like disease in mice.13 Thus, the NPM-ALK
chimeric protein appears to be a causative agent of ALCL. Recent
studies of ALCL cases revealed new variant fusions in about 20% of
ALK-positive ALCL, such as TFG-ALK, TPM3-ALK, and
ATIC-ALK.14-20 In all of these additional oncogenic ALK
rearrangements, the truncated ALK protein with its tyrosine kinase
domain is fused to a partner protein, that is capable of dimerization
and subsequent activation of the ALK portion.21
It has been shown that NPM-ALK can associate with and phosphorylate the
adaptor proteins SHC, Grb2, and IRS-1.21,22 However, mutational analysis of NPM-ALK that produced mutants unable to activate
SHC and IRS-1 could not reveal essential biologic functions of these 2 signal transducers for the oncogenicity of NPM-ALK.21,22 The biologic importance of Grb2 association with NPM-ALK has not yet
been assessed. A previous study from our laboratory indicated an
important role of PLC- Because of the sequence homology of NPM-ALK to LTK (leukocyte tyrosine
kinase), it has been hypothesized that NPM-ALK, like LTK, might
activate phosphatidylinositol 3-kinase (PI 3-kinase).22,24 A widely distributed isoform of PI 3-kinase is a heterodimer of a
110-kd (p110) catalytic subunit and an 85-kd (p85) regulatory subunit,
which is found in cellular complexes with ligand-activated growth
factor receptors and nonreceptor protein tyrosine kinases (PTKs).25,26 These interactions are mediated by the Src
homology 2 (SH2) domains of the p85 subunit of PI 3-kinase, which
associate with specific phosphotyrosine-containing motifs present in
tyrosine kinases.27-29
The association of p85 with activated tyrosine kinases is thought to
provide a signal sufficient for the activation of the p110 catalytic
subunit. After activation by PTK or G-protein-coupled receptors,
different classes of PI 3-kinases phosphorylate the D-3 position of
phosphatidylinositol (PI), phosphatidyl 4-phosphate (PI4P),
and PI4,5P2.26 The
3-phosphoinositide that is generated is able to bind to Pleckstrin
homology (PH) domains of signaling molecules and to activate various
downstream molecules, including the serine/threonine kinase
Akt/PKB.26,30-32 It has been shown that Akt is capable of
phosphorylating the BCL2 family member Bad, thereby suppressing apoptosis and promoting cell survival in a variety of cellular systems.33,34
In the present work, we demonstrate a role for PI 3-kinase in the
signaling pathways initiated by NPM-ALK and show its possible role in
the generation of an antiapoptotic signal important for the molecular
pathogenesis of ALCL.
Construction of expression plasmids and site-directed
mutagenesis
Antibodies
Cell culture and DNA transfection Karpas299 is a human cell line generated from NPM-ALK-positive T-cell lymphomas of adult ALCL patients, whereas JB6, SUP-M2, and SU-DHL1 are human NPM-ALK-positive T-cell lymphoma cell lines derived from infant ALCL patients.36 Both cell lines were cultured in RPMI 1640 medium with 5% fetal calf serum (FCS) (Seromed, Berlin, Germany). The murine pro-B lymphoid cell line Ba/F3 was maintained in RPMI 1640 with 10% FCS and 1.5 ng/mL murine recombinant interleukin-3 (IL-3) (R&D Systems, DPC Bierman GmbH, Wiesbaden, Germany). DNA transfections in Ba/F3 cells were performed by electroporation using the geneZAPPER (IBI, Madison, WI) at 250 mV and 950 µF with 25 µg DNA and 5 × 106 Ba/F3 cells in cold phosphate-buffered saline (PBS). After 48 hours, the transfected cells were selected with 1 mg/mL G418 (Serva, Heidelberg, Germany) for 14 days. Cos1 cells were cultured in DMEM medium containing 10% FCS. The transient transfection of Cos1 cells was carried out with Geneporter transfection reagent, according to the manufacturer's protocol (Biozym, Oldendorf, Germany).Glutathione-S-transferase-fusion proteins and pull-down assay The p85 SH2 domains cloned in pGEX-2TK were a kind gift of Prof Jean Y. J. Wang, University of California, San Diego, CA. The p85 N- and C-terminal SH2 glutathione-S-transferase (GST)-fusion proteins contained aa 323-463 and aa 562-724 of mouse p85, respectively. The SH2 GST-fusion proteins were expressed in Escherichia coli HB101 and affinity purified as described37 using glutathione-Sepharose (Pharmacia Biotech, Freiburg, Germany).For GST pull-down assays, 1 × 107 cells were solubilized in lysis buffer (10 mmol/L Tris-HCl [pH 7.4], 5 mmol/L EDTA, 130 mmol/L NaCl, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride, and 10 µg/mL each of phenantroline, aprotinin, leupeptin, and pepstatin), precleared with glutathione-beads, and incubated with 5 µg of GST-fusion proteins for 1 hour at 4°C. Protein complexes were collected on glutathione-Sepharose beads and subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Immunoprecipitation and immunoblotting Cells were suspended in lysis buffer 10 mmol/L Tris-HCl (pH 7.5), 130 mmol/L NaCl, 5 mmol/L EDTA, 0.5% Triton X-100, 1 mg bovine serum albumin (BSA) per milliliter, 20 mmol/L sodium phosphate (pH 7.5), 10 mmol/L sodium pyrophosphate (pH 7.0), 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1 mmol/L phenylmethylsulfonyl fluoride, 1x protease inhibitor cocktail (10 µmol/L benzamidine-HCl, 10 µg each of phenanthroline, aprotinin, leupeptin, and pepstatin per milliliter) and kept on ice for 30 minutes. Lysates were precleared by centrifugation and subjected to SDS-PAGE. Alternatively, the lysates were incubated for 2 to 12 hours with 1 to 2 µg antibody as indicated at 4°C. Immune complexes were precipitated with 30 µL protein A-Sepharose (Pharmacia Biotech, Freiburg, Germany) for 1 hour, washed 3 times with lysis buffer, and then boiled in 2% SDS sample buffer, followed by separation on SDS-polyacrylamide gels. Immunoblotting was performed with nitrocellulose membranes, and proteins were visualized by chemiluminescence, as recommended by the manufacturer (Amersham Life Science, Buckinghamshire, United Kingdom).Phosphopeptide competition assay The following tyrosine-phosphorylated peptides corresponding to the potential autophosphorylation sites of NPM-ALK were synthesized by BioTez GmbH, Berlin, Germany, using a SMPS 350 (Zinsser Analytik, Frankfurt, Germany): LRPQNpY17LFGCE, KADKDpY29HFKVD, AEAMNpY67EGSPI, QHLVVpY119RRKHQ, TIMTDpY152NPNYC, DYNPNpY156CFAGK, AFGEVpY191EGQVS, DIACGCQpY299LEENH, MARDIpY338RASYY, IYRASpY342YRKGG, IYRASYpY343RKG, IFSLGpY387MPYPS, LGYMPpY390PSKSN, PGPVpY418RIMTQ, IILERIEpY445CTQDP, LPIEpY461GPLVE, LWNPTpY567GSWFT, CGNVNpY644GYQQQ, NVNYGpY646QQQGL, PGAGHpY664EDTIL. p85-CSH2-GST bound on glutathione-Sepharose was first preincubated with 200 µmol/L phosphopeptide in 100 µL lysis buffer at 4°C for 1 hour, and then 1 × 106 Karpas299 cell lysate was added for an additional 1 hour. Complexes were washed 3 times, and the binding of NPM-ALK was detected by immunoblotting, as described above.PI 3-kinase assay PI 3-kinase activity in Ba/F3 cells was measured as described38 previously with minor modifications. Cell lysates were immunoprecipitated with antiphosphotyrosine antibody 4G10 in the lysis buffer described above for 3 hours at 4°C. Protein A-Sepharose beads were washed twice in lysis buffer, twice in buffer containing 0.2% NP-40 and 0.5 mol/L LiCl, and finally, in 0.15 mol/L NaCl and 10 mmol/L HEPES [pH 7.4]. The binding components were then eluted with 30 µL of 20 mmol/L phenyl phosphate for 30 minutes at 4°C. Kinase reaction was performed for 15 minutes at room temperature in the presence of 0.4 mg/mL phosphatidylinositol (Sigma), 40 µmol/L ATP, 30 mmol/L MgCl2, and 0.37 MBq (10 µCi) of [ -32P] ATP. The reaction was stopped by adding 100 µL of 1 N HCl, and the lipids were first extracted with 200 µL
chloroform/methanol (1:1; vol/vol), then washed once with methanol/1 N
HCl (1:1; vol/vol). The lipids in organic phase were separated by
thin-layer chromatrography (TLC) using silica gel 60 (Merck, Darmstadt,
Germany) with chloroform/methanol/H2O/NH4OH (43:38:7:5; vol/vol) and visualized by autoradiography.
Apoptosis analysis using flow cytometry JB6, parental Ba/F3 and NPM-ALK-transformed Ba/F3 cells were incubated with 200 nmol/L wortmannin for 3 days, with daily addition of fresh wortmannin to this concentration. The parental Ba/F3 cells were cultured with murine IL-3 as growth factor. Using a Fluorescein-FragEL DNA Fragmentation Detection Kit (Oncogene Research Products, Cambridge, MA), the exposed 3'-OH ends of DNA fragments generated in response to apoptotic signals were FITC-fluorescein-labeled by terminal deoxynucleotidyl transferase (TdT). Results were evaluated on a flow cytometer at 488 nm (Beckman Coulter, Krefeld, Germany).Generation of retrovirus stocks Retroviral supernatant was produced by transiently transfecting the Phoenix ecotropic producer line (Gary Nolan, Stanford, CA) with the Mig-EGFP or Mig-EGFP-NPM-ALK vectors.35 Medium was changed at 36 hours after transfection and collected after 48 hours. Titers of approximately 1 × 106 helper-virus-free viral particles were obtained as measured by FACS-titering of EGFP-positive infected Rat-1 cells.Soft agar assay Rat-1 fibroblast cells grown in DMEM supplemented with 10% FCS, 1% glutamin, and 1% penicillin/streptomycin (Gibco, Karlsruhe, Germany) were infected in the presence of 8 µg/mL polybrene (Sigma, Deisenhofen, Germany) with viral supernatant produced as described above. Two days after infection, 2.5 × 104 cells were plated in 60-mm plates in triplicates. The soft agar medium was made of 3 layers of IMDM/agarose as described previously.23 Ly294002 was added in a concentration of 10 or 20 µmol/L to the plates as indicated. Colonies were counted at 14 days after plating.Bone marrow transformation assays Balb/C mice were treated with 150 mg/kg 5-FU 4 days before bone marrow (BM) harvest. BM cells flushed from tibia and femur were preincubated for 1 day in BM medium (IMDM [Gibco, Berlin, Germany] supplemented with 30% FCS [Seromed], 1% BSA, 1% glutamin, 0.5% penicillin-streptomycin, 100 µmol/L 2-mercaptoethanol, and 1 µmol/L hydrocortisone) 50 ng/mL mSCF, 8 ng/mL mIL-3, and 12 ng/mL hIL-6 (all from R&D, Wiesbaden, Germany). After 1 day of preincubation, 4 × 106 BM cells were coincubated with 3 mL of viral supernatant and 1 mL of new medium, in the presence of the above mentioned growth factors and 4 µg/mL polybrene. New supernatant was added after 24 hours. Three days after infection, cells were washed in PBS. Transformation of cells in stromal-cell-dependent cultures was determined as described previously.39 Briefly, 5 × 105 infected cells were plated in BM media in 12-well plates in a volume of 2 mL with or without 100 pg/mL mIL-3. The 200 nmol/L wortmannin dissolved in DMSO or DMSO alone was added daily, as indicated and nonadherent cells were counted after 6 days.Methylcellulose assays were performed by plating 2 × 104 infected cells in 12-well plates in 1 mL methylcellulose medium (M4230, StemCell Technologies, Vancouver, British Columbia) with or without 10 pg/mL IL-3. The PI3-kinase inhibitor Ly294002 was added once as indicated at a concentration of 10 µmol/L. Colonies were counted 12 days after plating.
The regulatory subunit p85 of PI 3-kinase forms a complex with NPM-ALK in vivo via the C-terminal SH2 domain of p85 The regulatory p85 subunit of PI 3-kinase, which contains one SH3 and 2 SH2 domains, is responsible for the interaction of PI 3-kinase with activated tyrosine kinases.25,26 Coimmunoprecipitation experiments in NPM-ALK-expressing Ba/F3 cells (Figure 1A) as well as in cell lines established from patients with LCAL, Karpas299 cells (Figure 1B), and SUP-M2 cells (Figure 1C) demonstrated complex formation between p85 and NPM-ALK in vivo. An anti-ALK antibody was capable to coprecipitate p85 (Figure 1A,B, left panel, third lane; Figure 1C, left panel, second lane) and an antibody against p85 could coprecipitate NPM-ALK (Figure 1A,B,C, right panel, third lane) in all 3 cell lines tested. To identify the region of p85 responsible for complex formation with NPM-ALK, we carried out binding experiments with the C- and N-terminal SH2 domains of p85 in lysates of NPM-ALK-expressing Karpas299 cells. The p85-CSH2 domain, but not the p85-NSH2 domain, was shown to mediate this interaction (Figure 1D, left panel); the p85-NSH2 domain could precipitate tyrosine phosphorylated proteins (Figure 1D, right panel).
NPM-ALK activates PI 3-kinase and Akt After stimulation through tyrosine kinases, PI 3-kinase generates 3-phosphoinositides (PI3P), which function as important intracellular lipid messengers.25,26 As shown in Figure 2A, stable expression of NPM-ALK in Ba/F3 cells (Ba/F3 NPM-ALK), a murine pro-B-cell line, led to the generation of significant amounts of PI3P compared with parental Ba/F3 cells transfected with empty vector (Ba/F3 ) in cells cultured without
IL-3. PI 3-kinase activity was measured on phosphotyrosine
immunoprecipitates. Wortmannin treatment of NPM-ALK-expressing Ba/F3
cells resulted in a decrease of signal confirming that the product
measured is PI3P (data not shown and Figure
3D). Activation of PI 3-kinase has been
shown to elicit an antiapoptotic signal through the activation of
PKB/Akt.40 Therefore, we wished to determine the
activation status of Akt in NPM-ALK-expressing cells. As shown in
Figure 2B, a mobility shift of Akt in SDS-PAGE was demonstrable in
NPM-ALK-expressing cells compared with parental cells. This mobility
shift indicates phosphorylation and activation of
Akt.41
The growth of NPM-ALK-transformed Ba/F3 cells is suppressed by PI 3-kinase inhibitors To determine the role of PI 3-kinase in NPM-ALK-initiated transformation of hematopoietic cells, we used the specific PI 3-kinase inhibitor wortmannin42 in proliferation assays with NPM-ALK-transformed Ba/F3 cells. Wortmannin has been used in a number of studies to demonstrate the importance of the PI 3-kinase/Akt pathway for the transforming ability of oncogenic tyrosine kinases. Among others, Bcr-Abl has been demonstrated to use the PI 3-kinase/Akt pathway for its transforming ability.38,43,44 As previously published, and shown in Figure 3A, wortmannin at 200 nmol/L inhibited the growth of Bcr-Abl-transformed Ba/F3 cells by 50%. Similarly, wortmannin also suppressed the growth of NPM-ALK-transformed Ba/F3 cells at comparable concentrations (Figure 3B). At 300 nmol/L, wortmannin completely inhibited the growth of NPM-ALK-transformed Ba/F3 cells (Figure 3B). The PI 3-kinase/Akt/Bad pathway has been reported to function as one of the antiapoptotic signals initiated by IL-3 in Ba/F3 cells.34 Accordingly, wortmannin also inhibited the growth of parental Ba/F3 cells cultured in the presence of IL-3 (Figure 3C). However, in contrast to NPM-ALK-transformed Ba/F3 cells, the proliferation of parental Ba/F3 cells treated with 300 nmol/L wortmannin in the presence of IL-3 was reduced only by 50% (Figure 3C). Daily addition of wortmannin was sufficient to inhibit PI 3-kinase activity in NPM-ALK-expressing Ba/F3 cells (Figure 3D). These effects are likely due to the specific inhibition of the PI 3-kinase pathway because similar data were observed with another PI 3-kinase inhibitor, LY29400245 (Figure 4). Thus, the strong suppression of NPM-ALK-transformed Ba/F3 cells by PI 3-kinase inhibitors emphasized the importance of the PI 3-kinase pathway in these cells.
NPM-ALK-mediated transformation of primary mouse bone marrow cells is suppressed by PI 3-kinase inhibitors We have previously shown that NPM-ALK can induce soft agar growth of Rat-1 fibroblasts.23 NPM-ALK-induced soft agar growth can be significantly blocked by the single addition of LY294002 in a concentration-dependent manner (Figure 5A). Primary mouse bone marrow cells (BM cells) can form colonies in methylcellulose in the presence (Figure 5B, lower left panel) but not in the absence of IL-3 (data not shown).46 Retroviral transfection of NPM-ALK into primary BM cells induces the outgrowth of colonies in the absence of IL-3 in methycellulose (Figure 5B, upper left panel). These colonies were larger than the colonies obtained with IL-3 (compare Figure 5B, upper and lower left panel). A single addition of 10 µmol/L LY294002 prevented the outgrowth of these colonies (Figure 5B, upper right panel). In contrast, addition of LY294002 decreased but did not significantly affect the growth of colonies in the presence of IL-3 (Figure 5B, compare lower right and left panel and absolute colony numbers given in the table). Thus, LY294002 suppresses the growth of NPM-ALK-transduced bone marrow in methylcellulose and this inhibitory effect is not due to unspecific toxicity.
We also performed cell transformation assays in stromal-cell-dependent cultures.39 In this assay, the oncogene-induced outgrowth of cells on a stromal layer in the absence of growth factors is measured. As shown in Figure 5C, wortmannin treatment does not significantly affect the outgrowth of cells in the presence of Il-3 (left 4 panels). However, in the absence of IL-3, NPM-ALK-induced outgrowth of BM cells is impaired by the treatment with wortmannin (Figure 5C, right 2 panels). Similarly, this implies that the inhibitory effect of wortmannin on NPM-ALK-expressing BM cells is specific and not due to unspecific toxicity. Wortmannin-induced apoptosis in NPM-ALK-transformed cells Wortmannin has been demonstrated to block the antiapoptotic pathway related to PI 3-kinase/Akt in a variety of cells.47-49 To further investigate the growth-inhibitory effect of wortmannin on NPM-ALK-transformed cells, we performed apoptosis assays to detect fragmented DNA in wortmannin-treated cells. DNA fragments were FITC-fluorescein-labeled and quantified using a flow cytometer. Incubation of parental Ba/F3 cells grown with IL-3 in 300 nmol/L wortmannin for 3 days (the same conditions used in Figure 3A-C) did not induce any detectable DNA fragmentation in this assay (Figure 6A). By contrast, the same treatment of NPM-ALK-transformed Ba/F3 cells led to a significant shift to apoptotic DNA fragmentation in these cells (compare Figure 6B and 6A). Consistent with this result, wortmannin also induced DNA fragmentation in JB6 cells, a cell line established from a patient with ALCL that has been shown to express NPM-ALK (Figure 6C). The level of NPM-ALK expression of JB-6 cells is comparable to Ba/F3 cells expressing NPM-ALK and somewhat lower than in other NPM-ALK-positive cell lines established from patients with ALCL (Figure 6D).
Suppression of Bad-induced apoptosis by NPM-ALK One mechanism of apoptosis inhibition by PI 3-kinase and Akt is phosphorylation and inactivation of the proapoptotic protein Bad. Phosphorylation of Bad inhibits apoptosis by preventing the protein from binding to and inhibiting the antiapoptotic proteins Bcl2 and Bcl-xL.33,50 Thus, overexpression of Bad in cells leads to apoptosis that can be antagonized by overexpression of constitutively activated Akt or PAK (p21-activated protein kinase), both of which are able to phosphorylate Bad.51,52 Therefore, we tested the ability of NPM-ALK to block Bad-induced apoptosis. The overexpression of Bad in Cos1 cells led to almost total cell death in the early stage of the transfection (data not shown). Therefore, we cotransfected Bcl2 with Bad to obtain viable cells.34 This approach allowed us to control the expression of Bad and to rule out the possibility that differences in apoptosis might be due to inhibition of Bad expression by NPM-ALK. Even when cotransfected with Bcl2, overexpression of Bad in Cos1 cells led to death of roughly 30% of cells (Figure 7A). Coexpression of NPM-ALK could rescue part of the cells (Figure 7A). Immunoblots showed comparable expression levels of Bad and Bcl2 in these cells (Figure 7B). Thus, NPM-ALK was capable of partially preventing Bad-induced apoptosis in Cos1 cells.
Phosphopeptide competition identifies NPM-ALK-Tyr418 as a potential binding site for the p85-CSH2 domain. To further define the importance of the PI 3-kinase pathway for the transforming activity of NPM-ALK, we attempted to identify the tyrosine-containing motif of NPM-ALK responsible for recruitment and activation of PI 3-kinase. A series of 11-residue-long peptides encompassing putative tyrosine autophosphorylation sites in NPM-ALK was synthesized with Fmoc-protected phosphotyrosine, and phosphopeptide competition experiments were performed. Binding studies with the C-terminal SH2 domain of p85 and lysates of NPM-ALK-expressing Karpas299 cells were performed in the presence of 200 µmol/L competing phosphopeptides. Among 21 phosphopeptides tested, only one totally blocked the binding of the p85-CSH2 domain to NPM-ALK (data not shown). The putative NPM-ALK autophosphorylation site Y418 with the sequence PGPVpY418RIMTQ matches the high-affinity consensus-binding motif "pYXXM" for the p85-SH2 domain.53 Thus, these studies suggested that Y418 is the tyrosine residue potentially responsible for recruiting PI 3-kinase.Mutation of Y418 of NPM-ALK does not prevent the binding of p85-CSH2 To test whether Y418 is in fact the binding site for the p85-CSH2 domain, we constructed a tyrosine-to-phenylalanine mutant of NPM-ALK (NPM-ALK-Y418F). WT-NPM-ALK and NPM-ALK-Y418F were stably expressed in Ba/F3 at comparable levels (Figure 8A, left panel). However, mutation of Tyr418 did not significantly affect the binding affinity of NPM-ALK to the p85-CSH2 domain (Figure 8A, right panel).
In addition, we constructed 2 other mutants of NPM-ALK, NPM-ALK-Y152F, and NPM-ALKY156F. Tyr156 of NPM-ALK is the published binding site for IRS-1.22,54 IRS-1 has been shown to recruit the adaptor molecules p85 and Grb2.55,56 Therefore, we speculated that NPM-ALK may activate PI 3-kinase by recruiting IRS-1. However, in GST pull-down experiments, both NPM-ALK-Y152F and -Y156F bound to the p85-CSH2 domain (Figure 8B, right panel). Furthermore, we constructed 18 additional tyrosine-to-phenylalanine mutants of NPM-ALK representing almost all potential autophosphorylation sites (data not shown).23 None of these point mutations abolished the binding of the p85 SH2 domain to NPM-ALK. Together, these results show that none of these single sites could be solely responsible for the binding of NPM-ALK to the p85-CSH2 domain. The NPM-ALK-Y156F-Y418F and -Y664F mutants activate PI 3-kinase Because none of our single tyrosine-to-phenylalanine mutations was able to abolish the binding of the p85-CSH2 domain to NPM-ALK, we constructed a double mutant containing tyrosine-to-phenylalanine substitutions of both Tyr156 and Tyr418. However, PI 3-kinase activity in cells expressing the double-mutant NPM-ALK or WT-NPM-ALK was comparable (Figure 9A), indicating that these phosphorylation sites are not essential for the activation of PI 3-kinase. Therefore, it is possible that an intermediary protein is involved in the complex formation of NPM-ALK and PI 3-kinase. Indeed, among several adaptor proteins tested, Gab2, Shc, and Crkl form a complex simultanously with NPM-ALK and p85 in KARPAS299 cells (Figure 10). Interestingly, Crkl and Gab2 but not Gab1 coprecipitated p85 more strongly than NPM-ALK, whereas Shc preferentially precipitated NPM-ALK. Thus, Gab2, Crkl, and Shc are candidates mediating activation of PI 3-kinase by an oncogenic tyrosine kinase.
We have previously demonstrated that Tyr664 of NPM-ALK is an in vivo
autophosphorylation site that is necessary for the activation of
PLC-
The oncoprotein NPM-ALK has been shown to transform cells by
recruiting specific signaling molecules, such as Grb2, IRS-1, Shc, and
PLC- PI 3-kinase and its downstream target PKB/Akt have been shown to play
an important role for the antiapoptotic function of IL-3 in
lymphocytes.32,58,59 Akt itself is involved in the phosphorylation of Bad, activation of NF- PI 3-kinase assays revealed the activation of PI 3-kinase by NPM-ALK and immunoblot analysis indicated the phosphorylation/activation of Akt by NPM-ALK. The specific PI 3-kinase inhibitors wortmannin and LY294002 were able to block NPM-ALK-induced IL-3-independent proliferation of Ba/F3 lymphocytes. Furthermore, these inhibitors prevented NPM-ALK-induced IL-3-independent growth and transformation of primary mouse BM cells. In addition, a clearly recognizable population of NPM-ALK-transformed Ba/F3 cells and cells from a patient with ALCL underwent apoptosis upon wortmannin treatment. Together, these data indicate a role for PI 3-kinase in the antiapoptotic function of NPM-ALK, both in vitro and in ALCL. Interestingly, parental Ba/F3 lymphocytes and primary mouse BM cells supplemented with IL-3 were not significantly affected by wortmannin concentrations already showing an inhibitory effect on NPM-ALK-expressing cells, although the IL-3-induced antiapoptotic phosphorylation of Bad through Akt is well established.33,34 However, there are reports showing that overexpression of dominant-negative p85 or treatment with wortmannin in IL-3-dependent cells can result in inhibition of Bad phosphorylation, but fail to induce apoptosis.62,63 Thus, this pathway seems to be indispensable for NPM-ALK-induced prevention of apoptosis but not for IL-3-induced inhibition of apoptotic death. The apoptotic cascade is triggered by the loss of integrity of the outer mitochondrial membrane accompanied by release of cytochrome c, which is able to activate protease-activating factor and subsequently the caspase cascade.64 Akt is able to prevent caspase activation by maintaining mitochondrial integrity, and presumably, at least in part, by regulation of the proapoptotic Bcl2 family member Bad.51 Akt phosphorylates Bad and thereby deactivates its proapoptotic function.33 Further, it has been shown that overexpression of Bad can lead to apoptosis in a wide variety of cell lines,51,52,65 and that this induction of apoptosis can be inhibited by overexpression of constitutively activated Akt.51 NPM-ALK counteracted the apoptotic effects of Bad and partially rescued Cos1 cells from Bad-induced death. These data clearly revealed the antiapoptotic function of NPM-ALK, which is likely initiated through the PI 3-kinase/Akt pathway. We have also observed that Karpas299 cells are totally resistant to apoptotic signals triggered by anti-CD95 antibody although this ALCL cell line expresses CD95 after treatment with anti-CD3 antibody (R.-Y.B. and J.D., unpublished observations, 2000). This finding is consistent with previous reports showing protection of CD95-mediated apoptosis by activation of the PI 3-kinase/Akt pathway in T-leukemia cells66 and the ability of Bcr-Abl, which also activates PI 3-kinase and Akt, to block CD95-induced apoptosis.67 In our efforts to identify the binding site of the P85-CSH2 domain on NPM-ALK, we first identified NPM-ALK-Y418 as the only potential binding site in phosphopeptide competition assays. However, mutation of this site failed to abolish binding in cell lysates. A possible explanation might be that tyrosine residue 418 is not autophosphorylated or it is not accessible to the p85-SH2 domain in vivo. An indirect interaction of NPM-ALK with p85 through other adaptor molecules has to be taken into consideration. NPM-ALK-Tyr156 has been described as an IRS-1 binding site.22 IRS-1 can recruit PI 3-kinase and could thus serve as an adaptor for NPM-ALK. However, even double mutations of Tyr418F and Tyr156F did not reduce the binding affinity of NPM-ALK for p85 or the PI 3-kinase activity in NPM-ALK-expressing Ba/F3 cells. Given the numerous adaptor molecules that can function as linkers between tyrosine kinases and SH2 domains of downstream proteins, like Crk, Crkl, and Cbl,64-71 a complex involving p85, NPM-ALK, and an adaptor molecule is likely. Indeed, we can demonstrate a simultaneous complex among NPM-ALK, p85, and Gab2 or Shc or Crkl, respectively. Thus, Gab2, Crkl, and Shc are candidates linking NPM-ALK to PI 3-kinase via the regulatory subunit p85. Further studies are necessary to exactly determine the role of this adaptor proteins for NPM-ALK-mediated oncogenicity. We have demonstrated a mechanism by which the oncoprotein NPM-ALK triggers an antiapoptotic signal via PI 3-kinase/Akt. Interestingly, the v-Akt sequence was originally isolated from murine thymic lymphomas.72 This constitutively activated v-Akt is capable of initiating thymic lymphomas after inoculation of susceptible mouse strains and revealed high oncogenicity in the T-cell line 5675.73,74 Because NPM-ALK is associated with T-cell lymphomas, the activation status of Akt in tumor material from patients with ALCL should be interesting to determine. Specific therapies designed to inhibit PI 3-kinase activity might then be of potential interest for the treatment of NPM-ALK-related ALCL.
We are grateful to K. Schwarz for her crucial help in apoptotic analysis. We thank P. Seipel for excellent technical assistance.
Submitted March 23, 2000; accepted August 30, 2000.
Supported by a grant from the Wilhelm-Sander Stiftung and Mildred-Scheel Stiftung to J.D., by SFB grant No. 456 to J.D. and C.P. and National Cancer Institute (NCI) grant CA69129 and CORE grant CA21765 to S.W.M., and the American-Lebanese Associated Charities (ALSAC), St Jude Children's Research Hospital.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Justus Duyster, Department of Internal Medicine III, Laboratory of Leukemogenesis, Technical University of Munich, Ismaningerstr 22, 81675 Munich, Germany; email: justus.duyster{at}lrz.tum.de.
1.
Kadin ME.
Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy.
J Clin Oncol.
1994;12:884-887 2. Mason DY, Bastard C, Rimokh R, et al. CD30-positive large-cell lymphomas (`Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161-168[Medline] [Order article via Infotrieve].
3.
Morris SW, Kirstein MN, Valentine MB, et al.
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non- Hodgkin's lymphoma.
Science.
1994;263:1281-1284 4. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line AMS3. Oncogene. 1994;9:1567-1574[Medline] [Order article via Infotrieve]. 5. Stein H, Dallenbach F. Neoplastic Hematopathology. Baltimore, MD: Williams & Wilkins; 1992:675-714.
6.
Stein H, Herbst H, Anagnostopoulos I, Niedobitek G, Dallenbach F, Kratzsch HC.
The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma.
Ann Oncol.
1991;2:33-38 7. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56:379-390[Medline] [Order article via Infotrieve]. 8. Chan WY, Liu QR, Borjigin J, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry. 1989;28:1033-1039[Medline] [Order article via Infotrieve]. 9. Dumbar TS, Gentry GA, Olson MO. Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry. 1989;28:9495-9501[Medline] [Order article via Infotrieve]. 10. Schmidt ZM, Franke WW. DNA cloning and amino acid sequence determination of a major constituent protein of mammalian nucleoli: correspondence of the nucleoplasmin-related protein NO38 to mammalian protein B23. Chromosoma. 1988;96:417-426[Medline] [Order article via Infotrieve]. 11. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14:439-449[Medline] [Order article via Infotrieve]. 12. Morris SW, Naeve C, Mathew P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:2175-2188[Medline] [Order article via Infotrieve].
13.
Kuefer MU, Look AT, Pulford K, et al.
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
Blood.
1997;90:2901-2910
14.
Falini B, Pulford K, Pucciarini A, et al.
Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.
Blood.
1999;94:3509-3515
15.
Hernandez L, Pinyol M, Hernandez S, et al.
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.
Blood.
1999;94:3265-3268
16.
Lamant L, Dastugue N, Pulford K, Delsol G, Mariame B.
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Blood.
1999;93:3088-3095
17.
Ma Z, Cools J, Marynen P, et al.
Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Blood.
2000;95:2144-2149
18.
Rosenwald A, Ott G, Pulford K, et al.
t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma.
Blood.
1999;94:362-364
19.
Trinei M, Lanfrancone L, Campo E, et al.
A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
Cancer Res.
2000;60:793-798
20.
Wlodarska I, De Wolf-Peeters C, Falini B, et al.
The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma.
Blood.
1998;92:2688-2695 21. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma- associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol. 1997;17:2312-2325[Abstract].
22.
Fujimoto J, Shiota M, Iwahara T, et al.
Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).
Proc Natl Acad Sci U S A.
1996;93:4181-4186
23.
Bai RY, Dieter P, Peschel C, Morris SW, Duyster J.
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate ist mitogenicity.
Mol Cell Biol.
1998;18:6951-6961 24. Kozutsumi H, Toyoshima H, Hagiwara K, Yazaki Y, Hirai H. Human ltk receptor tyrosine kinase binds to PLC-gamma 1, PI3-K, GAP and Raf-1 in vivo. Oncogene. 1994;9:2991-2998[Medline] [Order article via Infotrieve]. 25. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell. 1991;64:281-302[Medline] [Order article via Infotrieve]. 26. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol. 1999;11:219-225[Medline] [Order article via Infotrieve]. 27. Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell. 1991;65:75-82[Medline] [Order article via Infotrieve]. 28. Otsu M, Hiles I, Gout I, et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell. 1991;65:91-104[Medline] [Order article via Infotrieve]. 29. Skolnik EY, Margolis B, Mohammadi M, et al. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell. 1991;65:83-90[Medline] [Order article via Infotrieve]. 30. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599-602[Medline] [Order article via Infotrieve]. 31. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789[Medline] [Order article via Infotrieve]
32.
Franke TF, Kaplan DR, Cantley LC, Toker A.
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science.
1997;275:665-668 33. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241[Medline] [Order article via Infotrieve].
34.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G.
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science.
1997;278:687-689
35.
Pear WS, Miller JP, Xu L.
et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Blood.
1998;92:3780-3792
36.
Morgan R, Smith SD, Hecht BK, et al.
Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis.
Blood.
1989;73:2155-2164 37. Smith DB, Johnson KS. Single-step purification of polypeptide expressed in Escherichia coli as fusions with glutathione-S-transferase. Gene. 1988;67:31-40[Medline] [Order article via Infotrieve].
38.
Skorski T, Kanakaraj P, Nieborowska SM, et al.
Phosphatidylinositol-3 kinase activity is regulated by Bcr-Abl and is required for the growth of Philadelphia chromosome-positive cells.
Blood.
1995;86:726-736
39.
McLaughlin J, Chianese E, Witte ON.
In vitro transformation of immature hematopoetic cells by the p210 bcr/abl oncogene product of the Philadelphia chromosome.
Proc Natl Acad Sci U S A.
1987;84:6558-6562 40. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435-437[Medline] [Order article via Infotrieve]. 41. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541-6551[Medline] [Order article via Infotrieve].
42.
Yano H, Nakanishi S, Kimura K, et al.
Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells.
J Biol Chem.
1993;268:25846-52586
43.
Jain SK, Susa M, Keeler ML, Carlesso N, Druker B, Varticovski L.
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Blood.
1996;88:1542-1550 44. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161[Medline] [Order article via Infotrieve].
45.
Yao R, Cooper GM.
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science.
1995;267:2003-2006
46.
Gishizky ML, Witte ON.
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
Science.
1992;256:836-839
47.
Eves EM, Xiong W, Bellacosa A, et al.
Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line.
Mol Cell Biol.
1998;18:2143-2152 48. Goruppi S, Ruaro E, Varnum B, Schneider C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol. 1997;17:4442-4453[Abstract]. 49. Nishida K, Kaziro Y, Satoh T. Anti-apoptotic function of Rac in hematopoietic cells. Oncogene. 1999;18:407-415[Medline] [Order article via Infotrieve]. 50. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X. Cell. 1996;87:619-628[Medline] [Order article via Infotrieve].
51.
Kennedy SG, Kandel ES, Cross TK, Hay N.
Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria.
Mol Cell Biol.
1999;19:5800-5810
52.
Schurmann A, Mooney AF, Sanders LC, et al.
p21-Activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis.
Mol Cell Biol.
2000;20:453-461 53. Songyang Z, Shoelson SE, Chaudhuri M, et al. SH2 domains recognize specific phosphopeptide sequences. Cell. 1993;72:767-778[Medline] [Order article via Infotrieve]. 54. Eck MJ, Dhe-Paganon S, Trub T, Nolte RT, Shoelson SE. Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell. 1996;85:695-705[Medline] [Order article via Infotrieve]. 55. Backer JM, Myers MG Jr, Shoelson SE, et al. Phosphatidylinositol 3-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992;11:3469-3479[Medline] [Order article via Infotrieve].
56.
Baltensperger K, Kozma LM, Cherniack AD, et al.
Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes.
Science.
1993;260:1950-1952 57. Hunter T. Oncoprotein networks. Cell. 1997;88:333-346[Medline] [Order article via Infotrieve] 58. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J. Phosphatidylinositol 3'kinase: one of the effectors of Ras. Philos Trans R Soc Lond B Biol Sci. 1996;351:225-231[Medline] [Order article via Infotrieve].
59.
Wennstrom S, Downward J.
Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor.
Mol Cell Biol.
1999;19:4279-4288 60. Khwaja A. Akt is more than just a Bad kinase. Nature. 1999;401:33-34[Medline] [Order article via Infotrieve].
61.
Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC.
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants.
Mol Cell Biol.
1991;11:1107-1113
62.
Craddock BL, Orchiston EA, Hinton HJ, Welham MJ.
Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling.
J Biol Chem.
1999;274:10633-10640 63. Minshall C, Arkins S, Freund GG, Kelley KW. Requirement for phosphatidylinositol 3-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol. 1996;156:939-947[Abstract].
64.
Thornberry NA, Lazebnik Y.
Caspases: enemies within.
Science.
1998;281:1312-1316
65.
Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R.
BAD enables ceramide to signal apoptosis via Ras and Raf-1.
J Biol Chem.
1998;273:30419-30426 66. Hausler P, Papoff G, Eramo A, Reif K, Cantrell DA, Ruberti G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur J Immunol. 1998;28:57-69[Medline] [Order article via Infotrieve].
67.
McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR.
Regulation of the Fas apoptotic cell death pathway by Abl.
J Biol Chem.
1995;270:22625-22631 68. Andoniou CE, Thien CB, Langdon WY. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Oncogene. 1996;12:1981-1989[Medline] [Order article via Infotrieve].
69.
Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ.
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
J Biol Chem.
1997;272:16170-16175 70. Jain SK, Langdon WY, Varticovski L. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase. Oncogene. 1997;14:2217-2228[Medline] [Order article via Infotrieve]. 71. Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996;12:839-846[Medline] [Order article via Infotrieve].
72.
Staal SP, Hartley JW, Rowe WP.
Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma.
Proc Natl Acad Sci U S A.
1977;74:3065-3067 73. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene. 1993;8:1957-1963[Medline] [Order article via Infotrieve].
74.
Staal SP, Hartley JW.
Thymic lymphoma induction by the AKT8 murine retrovirus.
J Exp Med.
1988;167:1259-1264
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  Y. P. Mosse, A. Wood, and J. M. Maris Inhibition of ALK Signaling for Cancer Therapy Clin. Cancer Res., September 15, 2009; 15(18): 5609 - 5614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lim, M. L. Carlson, D. K. Crockett, G. C. Fillmore, D. R. Abbott, O. F. Elenitoba-Johnson, S. R. Tripp, G. Z. Rassidakis, L. J. Medeiros, P. Szankasi, et al. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways Blood, August 20, 2009; 114(8): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-X. Cui, A. Kerby, F. K. E. McDuff, H. Ye, and S. D. Turner NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner Blood, May 21, 2009; 113(21): 5217 - 5227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Singh, J. H. Cho-Vega, Y. Davuluri, S. Ma, F. Kasbidi, C. Milito, P. A. Lennon, E. Drakos, L. J. Medeiros, R. Luthra, et al. Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma Cancer Res., March 15, 2009; 69(6): 2550 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Tartari, R. H. Gunby, A. M. L. Coluccia, R. Sottocornola, B. Cimbro, L. Scapozza, A. Donella-Deana, L. A. Pinna, and C. Gambacorti-Passerini Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase J. Biol. Chem., February 15, 2008; 283(7): 3743 - 3750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, and G. Los Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther., December 1, 2007; 6(12): 3314 - 3322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Staber, P. Vesely, N. Haq, R. G. Ott, K. Funato, I. Bambach, C. Fuchs, S. Schauer, W. Linkesch, A. Hrzenjak, et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling Blood, November 1, 2007; 110(9): 3374 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Amin and R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood, October 1, 2007; 110(7): 2259 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galietta, R. H. Gunby, S. Redaelli, P. Stano, C. Carniti, A. Bachi, P. W. Tucker, C. J. Tartari, C.-J. Huang, E. Colombo, et al. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma Blood, October 1, 2007; 110(7): 2600 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Leventaki, E. Drakos, L. J. Medeiros, M. S. Lim, K. S. Elenitoba-Johnson, F. X. Claret, and G. Z. Rassidakis NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma Blood, September 1, 2007; 110(5): 1621 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Voena, C. Conte, C. Ambrogio, E. Boeri Erba, F. Boccalatte, S. Mohammed, O. N. Jensen, G. Palestro, G. Inghirami, and R. Chiarle The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration Cancer Res., May 1, 2007; 67(9): 4278 - 4286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Galkin, J. S. Melnick, S. Kim, T. L. Hood, N. Li, L. Li, G. Xia, R. Steensma, G. Chopiuk, J. Jiang, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK PNAS, January 2, 2007; 104(1): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fawal, F. Armstrong, S. Ollier, H. Dupont, C. Touriol, B. Monsarrat, G. Delsol, B. Payrastre, and D. Morello A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK Blood, October 15, 2006; 108(8): 2780 - 2788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lim and K. S. J. Elenitoba-Johnson Mass Spectrometry-based Proteomic Studies of Human Anaplastic Large Cell Lymphoma Mol. Cell. Proteomics, October 1, 2006; 5(10): 1787 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qiu, R. Lai, Q. Lin, E. Lau, D. M. Thomazy, D. Calame, R. J. Ford, L. W. Kwak, R. A. Kirken, and H. M. Amin Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells Blood, October 1, 2006; 108(7): 2407 - 2415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Y.-Y. Hsu, P. B. Johnston, K. A. Burke, and Y. Zhao The Expression of CD30 in Anaplastic Large Cell Lymphoma Is Regulated by Nucleophosmin-Anaplastic Lymphoma Kinase-Mediated JunB Level in a Cell Type-Specific Manner. Cancer Res., September 15, 2006; 66(18): 9002 - 9008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Quintanilla-Martinez, S. Pittaluga, C. Miething, M. Klier, M. Rudelius, T. Davies-Hill, N. Anastasov, A. Martinez, A. Vivero, J. Duyster, et al. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma Blood, September 15, 2006; 108(6): 2029 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, P. W. Manley, J. Mestan, J. Sanger, C. Peschel, and J. Duyster Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood, August 15, 2006; 108(4): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol. Cell. Biol., August 1, 2006; 26(16): 6209 - 6222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. Cancer Res., July 1, 2006; 66(13): 6589 - 6597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Honorat, A. Ragab, L. Lamant, G. Delsol, and J. Ragab-Thomas SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling Blood, May 15, 2006; 107(10): 4130 - 4138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Oyarzo, L. J. Medeiros, C. Atwell, M. Feretzaki, V. Leventaki, E. Drakos, H. M. Amin, and G. Z. Rassidakis c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma Blood, March 15, 2006; 107(6): 2544 - 2547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wan, M. S. Albom, L. Lu, M. R. Quail, N. C. Becknell, L. R. Weinberg, D. R. Reddy, B. P. Holskin, T. S. Angeles, T. L. Underiner, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells Blood, February 15, 2006; 107(4): 1617 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D'Escamard, E. Pellegrino, C. Ponzetto, G. Palestro, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas Blood, January 15, 2006; 107(2): 689 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Gouzi, C. Moog-Lutz, M. Vigny, and N. Brunet-de Carvalho Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells J. Cell Sci., December 15, 2005; 118(24): 5811 - 5823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ambrogio, C. Voena, A. D. Manazza, R. Piva, L. Riera, L. Barberis, C. Costa, G. Tarone, P. Defilippi, E. Hirsch, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase Blood, December 1, 2005; 106(12): 3907 - 3916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-y. Ren, E. Bolton, M. G. Mohi, A. Morrione, B. G. Neel, and T. Skorski Phosphatidylinositol 3-Kinase p85{alpha} Subunit-Dependent Interaction with BCR/ABL-Related Fusion Tyrosine Kinases: Molecular Mechanisms and Biological Consequences Mol. Cell. Biol., September 15, 2005; 25(18): 8001 - 8008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bacchiocchi, G. Baldanzi, D. Carbonari, C. Capomagi, E. Colombo, W. J. van Blitterswijk, A. Graziani, and F. Fazioli Activation of {alpha}-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase Blood, September 15, 2005; 106(6): 2175 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moog-Lutz, J. Degoutin, J. Y. Gouzi, Y. Frobert, N. B.-d. Carvalho, J. Bureau, C. Creminon, and M. Vigny Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin J. Biol. Chem., July 15, 2005; 280(28): 26039 - 26048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, D. R. Veach, H. van der Kuip, W. E. Aulitzky, J. Sanger, P. Seipel, W. G. Bornmann, C. Peschel, B. Clarkson, and J. Duyster A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor Blood, February 15, 2005; 105(4): 1652 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Rassidakis, M. Feretzaki, C. Atwell, I. Grammatikakis, Q. Lin, R. Lai, F.-X. Claret, L. J. Medeiros, and H. M. Amin Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma Blood, January 15, 2005; 105(2): 827 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bonzheim, E. Geissinger, S. Roth, A. Zettl, A. Marx, A. Rosenwald, H. K. Muller-Hermelink, and T. Rudiger Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling Blood, November 15, 2004; 104(10): 3358 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Motegi, J. Fujimoto, M. Kotani, H. Sakuraba, and T. Yamamoto ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth J. Cell Sci., July 1, 2004; 117(15): 3319 - 3329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-L. Gu, Z. Tothova, B. Scheijen, J. D. Griffin, D. G. Gilliland, and D. W. Sternberg NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a Blood, June 15, 2004; 103(12): 4622 - 4629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonvini, H. D. Rosa, N. Vignes, and A. Rosolen Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin: Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein Cancer Res., May 1, 2004; 64(9): 3256 - 3264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Schlette, L. J. Medeiros, A. Goy, R. Lai, and G. Z. Rassidakis Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma J. Clin. Oncol., May 1, 2004; 22(9): 1682 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Burchert, D. Cai, L. C. Hofbauer, M. K. R. Samuelsson, E. P. Slater, J. Duyster, M. Ritter, A. Hochhaus, R. Muller, M. Eilers, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2 Blood, May 1, 2004; 103(9): 3480 - 3489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. L. Coluccia, S. Perego, L. Cleris, R. H. Gunby, L. Passoni, E. Marchesi, F. Formelli, and C. Gambacorti-Passerini Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo Blood, April 1, 2004; 103(7): 2787 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cussac, C. Greenland, S. Roche, R.-Y. Bai, J. Duyster, S. W. Morris, G. Delsol, M. Allouche, and B. Payrastre Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity Blood, February 15, 2004; 103(4): 1464 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, D. R. Veach, W. T. Miller, W. Li, J. Sanger, C. Peschel, W. G. Bornmann, B. Clarkson, and J. Duyster Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors Cancer Res., October 1, 2003; 63(19): 6395 - 6404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wohlbold, H. van der Kuip, C. Miething, H.-P. Vornlocher, C. Knabbe, J. Duyster, and W. E. Aulitzky Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) Blood, September 15, 2003; 102(6): 2236 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli, V. Leventaki, A. Schmitt-Graeff, M. Herling, H. M. Amin, and R. Lai Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma Clin. Cancer Res., September 1, 2003; 9(10): 3692 - 3699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ouyang, R.-Y. Bai, F. Bassermann, C. von Klitzing, S. Klumpen, C. Miething, S. W. Morris, C. Peschel, and J. Duyster Identification and Characterization of a Nuclear Interacting Partner of Anaplastic Lymphoma Kinase (NIPA) J. Biol. Chem., August 8, 2003; 278(32): 30028 - 30036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishikori, Y. Maesako, C. Ueda, M. Kurata, T. Uchiyama, and H. Ohno High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease Blood, April 1, 2003; 101(7): 2789 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors Blood, March 1, 2003; 101(5): 1919 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Bowden, G. E. Stoica, and A. Wellstein Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase J. Biol. Chem., September 20, 2002; 277(39): 35862 - 35868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Raetz, S. L. Perkins, M. A. Carlson, K. P. Schooler, W. L. Carroll, and D. M. Virshup The Nucleophosmin-Anaplastic Lymphoma Kinase Fusion Protein Induces c-Myc Expression in Pediatric Anaplastic Large Cell Lymphomas Am. J. Pathol., September 1, 2002; 161(3): 875 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piccinini, R. Bacchiocchi, M. Serresi, C. Vivani, S. Rossetti, C. Gennaretti, D. Carbonari, and F. Fazioli A Ligand-inducible Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase Chimera Promotes Mitogenesis and Transforming Properties in 3T3 Cells J. Biol. Chem., June 14, 2002; 277(25): 22231 - 22239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. ten Berge, C. J. L. M. Meijer, D. F. Dukers, J. A. Kummer, B. A. Bladergroen, W. Vos, C. E. Hack, G. J. Ossenkoppele, and J. J. Oudejans Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma Blood, May 29, 2002; 99(12): 4540 - 4546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hernandez, S. Bea, B. Bellosillo, M. Pinyol, B. Falini, A. Carbone, G. Ott, A. Rosenwald, A. Fernandez, K. Pulford, et al. Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas : Identification of a New TFG-ALKXL Chimeric Gene with Transforming Activity Am. J. Pathol., April 1, 2002; 160(4): 1487 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bassermann, T. Jahn, C. Miething, P. Seipel, R.-Y. Bai, S. Coutinho, V. L. Tybulewicz, C. Peschel, and J. Duyster Association of Bcr-Abl with the Proto-oncogene Vav Is Implicated in Activation of the Rac-1 Pathway J. Biol. Chem., March 29, 2002; 277(14): 12437 - 12445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Passoni, A. Scardino, C. Bertazzoli, B. Gallo, A. M. L. Coluccia, F. A. Lemonnier, K. Kosmatopoulos, and C. Gambacorti-Passerini ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes Blood, March 15, 2002; 99(6): 2100 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonvini, T. Gastaldi, B. Falini, and A. Rosolen Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin Cancer Res., March 1, 2002; 62(5): 1559 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dierov, Q. Xu, R. Dierova, and M. Carroll TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle Blood, March 1, 2002; 99(5): 1758 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Turturro, M. D. Arnold, A. Y. Frist, and K. Pulford Model of Inhibition of the NPM-ALK Kinase Activity by Herbimycin A Clin. Cancer Res., January 1, 2002; 8(1): 240 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski, and M. A. Wasik Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma J. Immunol., January 1, 2002; 168(1): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jahn, P. Seipel, S. Coutinho, C. Miething, C. Peschel, and J. Duyster Grb4/Nckbeta Acts as a Nuclear Repressor of v-Abl-induced Transcription from c-jun/c-fos Promoter Elements J. Biol. Chem., November 9, 2001; 276(46): 43419 - 43427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. van der Kuip, A. W. Goetz, C. Miething, J. Duyster, and W. E. Aulitzky Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis Blood, September 1, 2001; 98(5): 1532 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sun, J. E. Paciga, R. I. Feldman, Z.-q. Yuan, D. Coppola, Y. Y. Lu, S. A. Shelley, S. V. Nicosia, and J. Q. Cheng Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, Activated in Breast Cancer, Regulates and Is Induced by Estrogen Receptor {alpha} (ER{alpha}) via Interaction between ER{alpha} and PI3K Cancer Res., August 1, 2001; 61(16): 5985 - 5991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Rassidakis, A. H. Sarris, M. Herling, R. J. Ford, F. Cabanillas, T. J. McDonnell, and L. J. Medeiros Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage Am. J. Pathol., August 1, 2001; 159(2): 527 - 535. [Abstract] [Full Text]
|
|
|
|
|
|
C. Villalva, F. Bougrine, G. Delsol, and P. Brousset Bcl-2 Expression in Anaplastic Large Cell Lymphoma Am. J. Pathol., May 1, 2001; 158(5): 1889 - 1890. [Full Text] [PDF]
|
|
|
|
|
|
M. H.-H. Nguyen, J. M.-Y. Ho, B. K. Beattie, and D. L. Barber TEL-JAK2 Mediates Constitutive Activation of the Phosphatidylinositol 3'-Kinase/Protein Kinase B Signaling Pathway J. Biol. Chem., August 24, 2001; 276(35): 32704 - 32713. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
M) served as
a negative control for the immunoprecipitation. (D) Left panel:
1 × 107 Karpas299 cells were lysed, then incubated with
the C- or N-terminal SH2 domain GST-fusion proteins for 1 hour at
4°C. The bound (B) and the flow-through (FT) fractions were collected
with glutathione-Sepharose, subjected to 7.5% SDS-PAGE, and analyzed
by anti-ALK immunoblotting. Right panel: Lysates of
1 × 107 Ba/F3 cells cultured with and without IL-3 for 2 hours as indicated were incubated with the N-terminal p85 SH2 domain or
GST as control for 1 hour at 4°C and the bound fractions were
collected with glutathione-Sepharose. Input and bound fractions were
subjected to 7.5% SDS-PAGE, and analyzed by antiphosphotyrosine
immunoblotting.
, 100 nmol/L; 
, 300 nmol/L) or with
DMSO as control (
) with daily addition of wortmannin and DMSO. The
Bcr-Abl- and NPM-ALK-transformed Ba/F3 cells were cultured without
IL-3. The number of viable cells was determined by trypan blue staining
at the days indicated. Results are representative of at least 3 independent experiments. (D) PI 3-kinase activity was measured as
described in the legend to Figure 
, no wortmannin. The bars represent the
percentage of cells present in the supernatant after 6 days of culture
and the number of cells infected with control vector and supplemented
with IL-3 was arbitrarily set as 100%. Data represent means ± SD
of at least 2 independent experiments.
) or DMSO as
control (
B, inhibition of caspase-9, and reduction of the transcription of the Fas ligand, all of which contribute to its antiapoptotic function.